The Clinical Research Unit (CRU) is critical to the conduct of clinical research at the Abramson Cancer Center (ACC). This core is a centralized administrative unit that coordinates protocol management, budget and financial analysis, regulatory affairs expertise, research nursing support, and data management for therapeutic clinical trials conducted by ACC investigators. The CRU supports peer-reviewed funded clinical research projects, invesfigator-initiated clinical trials, cooperative group trials, and industry-sponsored trials. All trials supported by the CRU are approved by the ACC Clinical Trials Scientific Review and Monitoring Committee and are subject to ACC Data and Safety Monitoring Committee internal audits. By providing the necessary infrastructure for the transfer of preclinical discoveries into the clinic, this core is central to the ACC mission to support translational research and high impact clinical trials. The availability of a senior scientific leader, who is an expert in clinical trials management, as well as highly skilled research personnel, allows ACC clinical invesfigators to develop and conduct a comprehensive range of clinical trials for all types of cancer that involve both novel agents and innovative treatment approaches. In response to the 2004 CCSG critique ofthe CRU, the ACC has implemented Velos eResearch, a clinical trials management system. This information system will improve efficiency of CRU operations and ensure data standardization and regulatory compliance. Additional changes in the clinical research infrastructure have enhanced the function of this core. These include the establishment of disease-specific research groups charged with the responsibility of managing their portfolio of clinical trials, based upon scienfific goals and available resources; the establishment ofthe Strategic Planning and Resource Committee, a centralized group that reviews a proposed protocol to be certain that adequate resources are available to support the trial and that the budget is appropriate. These additional reviews help assure that the resources ofthe CRU are focused on the highest priority clinical trials conducted by ACC members. From 1/2009 to 12/2009 49 new therapeutic clinical trials have been activated by the CRU. CCSG support represents 20% ofthe core's proposed budget with the remaining funding coming from other grants/contracts and institutional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593284
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$458,731
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Dannoon, Shorouk; Ganguly, Tanushree; Cahaya, Hendry et al. (2016) Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem 59:5684-94
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Karunamuni, Roshan; Naha, Pratap C; Lau, Kristen C et al. (2016) Development of silica-encapsulated silver nanoparticles as contrast agents intended for dual-energy mammography. Eur Radiol 26:3301-9
Vachani, Anil; Wong, Yu-Ning; Israelite, Jennifer et al. (2016) Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care :
Ruella, Marco; Barrett, David M; Kenderian, Saad S et al. (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126:3814-3826
Heneghan, Mallorie B; Rheingold, Susan R; Li, Yimei et al. (2016) Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16:223-229.e2
Clark, A S; DeMichele, A; Mankoff, D (2016) HER2 imaging in the ZEPHIR study. Ann Oncol 27:555-7
Bartlett, Edmund K; Peters, Madalyn G; Blair, Anne et al. (2016) Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Ann Surg Oncol 23:250-6
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Zhang, Zi; Brown, Justin C; O'Malley Jr, Bert W et al. (2016) Post-treatment weight change in oral cavity and oropharyngeal squamous cell carcinoma. Support Care Cancer 24:2333-40

Showing the most recent 10 out of 848 publications